Antibiotic Prophylaxis in Rhinoplasty

Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics

Status

Enrolling by invitation

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04194216

Enrollment

864

Registered

2019-12-11

Start date

2020-05-20

Completion date

2027-04-20

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal Obstruction, Nasal Surgical Procedures

Keywords

Rhinoplasty, Antibiotic prophylaxis

Brief summary

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Detailed description

The study will consist of 2 treatment arms: Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

Interventions

DRUGIntra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Treatment Arm A

DRUGIntra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

Treatment Arm B

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Applicable Clinical Trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Adult patients (aged 18years and older)

Exclusion criteria

* Prior rhinoplasty * Any exogenous (non-nasal) grafts/implants * Immune deficiency (DM, meds, other) * History of radiotherapy to nose

Design outcomes

Primary

Measure	Time frame	Description
Postoperative Infection Rate	Seven days	Postoperatively, infection rates between treatment arms will be compared

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSam P Most, MD

Stanford Facial Plastic and Reconstructive Surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026